Expert Interview
A Third View: A look at the potential of LY3462817 (Peresolimab) - a PD-1 Antibody Agonist in Rheumatoid Arthritis
Ticker(s): LLYInstitution: Phoenix Children's Hospital
- Board-certified in pediatric rheumatology and Division Chief of pediatric rheumatology at Phoenix Children's Hospital.
- Clinical interests include the epidemiology of systemic juvenile idiopathic arthritis and mixed connective tissue disease, vasculopathy in juvenile dermatomyositis, and adherence with medications in systemic lupus erythematosus.
- Currently manages 200 patients with Rheumatoid Arthritis
- Familiar with the mechanism of action for Peresolimab
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
